 WALTHAM, Mass., Sept. 22, 2022 GLOBE NEWSWIRE -- TScan Therapeutics, Inc. Nasdaq: TCRX, a clinical-stage biopharmaceutical company focused on the development of T cell receptor TCR engineered T cell therapies TCR-T for the treatment of patients with cancer, today announced that management will participate in the following upcoming investor conferences: 